| Asthma |
NCT06191315: Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) |
|
|
| Recruiting | 3 | 90 | Europe, Canada, US, RoW | Dupilumab, SAR231893, Dupixent, Placebo | Sanofi, Regeneron Pharmaceuticals | Wheezing, Asthma | 12/28 | 12/28 | | |
NCT05555290: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction |
|
|
| Recruiting | 3 | 105 | US | PT027, PT007 | AstraZeneca | Asthma | 11/24 | 11/24 | | |
STEP, NCT06465485: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma |
|
|
| Recruiting | 3 | 200 | RoW | Benralizumab, Fasenra | AstraZeneca | Severe Eosinophilic Asthma | 10/25 | 07/26 | | |
Salsa, NCT05884970: In Vivo Efficacy of Salbutamol (Sandoz) Versus Salbutamol Ventolin (GSK) in Children With Asthma |
|
|
| Recruiting | 3 | 80 | Europe | "100 mcg Salbutamol Sandoz" and "300 mcg Salbutamol Sandoz", "100 mcg Salbutamol Sandoz" and "300 mcg Salbutamol Ventolin GSK", "100 mcg Salbutamol Ventolin GSK" and "300 mcg Salbutamol Sandoz", "100 mcg Salbutamol Ventolin GSK" and "300 mcg Salbutamol Ventolin GSK" | Canisius-Wilhelmina Hospital | Agents, Anti Asthmatic, Asthma in Children | 03/24 | 09/24 | | |
NCT06323213: Efficacy and Safety Study of 610 in Patients With Severe Asthma |
|
|
| Not yet recruiting | 3 | 480 | NA | 610, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Asthma | 06/26 | 09/26 | | |
| Active, not recruiting | 3 | 397 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Placebo | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 04/24 | 04/24 | | |
| Enrolling by invitation | 3 | 1600 | US | Dexpramipexole Dihydrochloride | Areteia Therapeutics | Eosinophilic Asthma | 06/27 | 06/27 | | |
NCT05505734: A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma |
|
|
| Active, not recruiting | 3 | 2518 | US | BDA MDI, AS MDI | Bond Avillion 2 Development LP, Parexel | Asthma | 03/25 | 03/25 | | |
ACADIA, NCT06307665: Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma |
|
|
| Recruiting | 3 | 440 | US | BDA MDI, PT027, AS MDI, PT007 | AstraZeneca, Parexel | Asthma | 10/27 | 10/27 | | |
| Not yet recruiting | 3 | 1038 | NA | Budesonide/formoterol, No other intervention names, standard of care, beclomethasone or budesonide & salbutamol or mentelukast | University of KwaZulu | Asthma | 05/25 | 05/26 | | |
| Active, not recruiting | 3 | 405 | RoW | Experimental: Tezepelumab, Tezepelumab, Placebo | AstraZeneca, Amgen | Asthma | 05/24 | 08/24 | | |
|
NCT05363202: To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma |
|
|
| Recruiting | 3 | 790 | RoW | Fluticasone propionate Inhalation Aerosol 44 mcg, FLOVENT HFA 44 mcg, Matching Placebo inhaler | Glenmark Pharmaceuticals Ltd. India | Bronchial Asthma | 05/24 | 08/24 | | |
NCT06261957: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants 12 Years of Age and Older With Asthma |
|
|
| Recruiting | 3 | 412 | Europe, Canada, US, RoW | Salbutamol HFA-134a, Salbutamol HFA-152a | GlaxoSmithKline | Asthma | 04/25 | 04/25 | | |
EXHALE-4, NCT05748600: A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma |
|
|
| Recruiting | 3 | 550 | Europe, US | Dexpramipexole Dihydrochloride, Placebo | Areteia Therapeutics | Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack | 03/25 | 04/25 | | |
VATHOS, NCT05202262 / 2021-002026-24: A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma |
|
|
| Recruiting | 3 | 630 | Europe, Canada, Japan, US, RoW | BFF MDI 320/9.6 μg, BFF, BFF MDI 160/9.6 μg, BD MDI 320 μg, BD, Open-label Symbicort TBH 320/9 μg, Symbicort TBH | AstraZeneca | Asthma | 03/25 | 03/25 | | |
NCT05400811: Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis |
|
|
| Not yet recruiting | 3 | 400 | Europe | MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL), Placebo subcutaneous, Placebo sublingual | Inmunotek S.L., BioClever 2005 S.L., NTS hub S.L | House Dust Mite Allergy, Perennial Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma | 07/24 | 07/25 | | |
NCT06461949: Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray |
|
|
| Recruiting | 3 | 132 | US | Dupilumab | National Institute on Deafness and Other Communication Disorders (NIDCD) | Allergic Fungal Rhinosinusitis (AFRS), Chronic Rhinosinusitis (CRS), Asthma, Nasal Polyps | 12/25 | 03/26 | | |
BAIYUN, NCT06471257: A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma |
|
|
| Not yet recruiting | 3 | 790 | RoW | Budesonide/Albuterol metered dose inhaler, MDI, PT027, Albuterol sulfate metered dose inhaler, MDI, PT007 | AstraZeneca | Asthma | 10/26 | 10/26 | | |
NCT05632549: The Possible Efficacy and Safety of L-carnitine and Biotin as Adjunctive Therapies in Children With Moderate Persistent Asthma |
|
|
| Active, not recruiting | 3 | 66 | RoW | Placebo, L-Carnitine 500Mg Oral Tablet, Biotin Capsules | Tanta University | Moderate Persistent Asthma | 08/24 | 08/24 | | |
LITHOS, NCT05755906 / 2021-003334-36: A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma |
|
|
| Recruiting | 3 | 340 | Europe, Canada, US, RoW | BFF MDI 160/9.6 μg BID (320/19.2μg/day), BFF, BD MDI 160 μg BID (320 μg/day), BD | AstraZeneca, AstraZeneca AB | Asthma | 01/25 | 01/25 | | |
| Active, not recruiting | 3 | 306 | Europe, US, RoW | Tezepelumab | AstraZeneca | Asthma | 09/24 | 09/24 | | |
NCT04937387: Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma |
|
|
| Recruiting | 3 | 356 | RoW | FF/VI, FF/UMEC/VI, ELLIPTA | GlaxoSmithKline | Asthma | 09/24 | 09/24 | | |
ESPIRE, NCT04233190: A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment |
|
|
| Recruiting | 3 | 472 | RoW | Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg, fumarato de formoterol di-hidratado 12mcg + budesonida 400mcg/fumarato de formoterol di-hidratado 62mcg + budesonida 200mcg | Eurofarma Laboratorios S.A. | Asthma Copd | 03/25 | 11/25 | | |
ARRIVAL, NCT06473779: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. |
|
|
| Not yet recruiting | 3 | 300 | NA | Tezepelumab, TEZSPIRE®, Budesonide/formoterol, SYMBICORT® pMDI, Albuterol/budesonide (AIRSUPRA®), AIRSUPRA®, Mannitol, ARIDOL®, Salbutamol, Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA | AstraZeneca, Fortrea | Severe Asthma | 06/27 | 06/27 | | |
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma |
|
|
| Recruiting | 3 | 292 | US, RoW | FF/UMEC/VI, ELLIPTA, FF/VI | GlaxoSmithKline | Asthma | 01/27 | 01/27 | | |
ETHA, NCT04651777: Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma |
|
|
| Active, not recruiting | 3 | 31 | Canada | FF/UMEC/VI, Trelegy | Dr. Grace Parraga, GlaxoSmithKline | Asthma | 08/23 | 12/24 | | |
| Recruiting | 3 | 138 | Europe | Budesonide/Formoterol fumarate dihydrate, Budesonide Formoterol (BF) Digihaler Digital System (DS) | Franciscus Gasthuis, Teva Pharmaceuticals USA | Asthma | 01/25 | 06/25 | | |
AZ-SWED, NCT04669288: AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department |
|
|
| Recruiting | 3 | 1476 | US | Azithromycin, Placebo | University of Arizona, University of Utah, Emory University, Morgan Stanley Children's Hospital, University of Pittsburgh, Children's Hospital and Health System Foundation, Wisconsin, Children's Hospital of Philadelphia, Children's Hospital Medical Center, Cincinnati, Boston Children's Hospital | Asthma, Wheezing | 11/25 | 06/26 | | |
| Recruiting | 3 | 894 | Europe | Bacterial Lysate, Placebo | Barts & The London NHS Trust, University of Aberdeen, University of Edinburgh, King's College London, University of Southampton, Menzies School of Health Research | Wheezing, Bronchiolitis, Asthma in Children | 03/25 | 03/25 | | |
| Recruiting | 3 | 90 | Europe | Tezepelumab, placebo | University Hospital, Montpellier | Airway Remodelling, Asthmatic | 12/25 | 06/26 | | |
| Recruiting | 3 | 2200 | Europe, Canada, Japan, US, RoW | BGF MDI 320/28.8/9.6 μg, BGF, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF, BFF pMDI 320/9 μg, Symbicort® | AstraZeneca | Asthma | 03/25 | 03/25 | | |
| Recruiting | 3 | 2200 | Europe, US, RoW | BGF MDI 320/28.8/9.6 μg, BGF, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF, BFF pMDI 320/9 μg, Symbicort® | AstraZeneca | Asthma | 03/25 | 03/25 | | |
| Active, not recruiting | 3 | 365 | Europe, Canada, Japan, US, RoW | Dupilumab (SAR231893/REGN668), Asthma controller therapies (incl. prednisone/prednisolone), Asthma reliever therapies | Sanofi, Regeneron Pharmaceuticals | Asthma | 03/25 | 03/25 | | |
|
SUNRISE, NCT05398263: Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma |
|
|
| Recruiting | 3 | 207 | Europe, Canada, US, RoW | Tezepelumab, Placebo | AstraZeneca, Amgen | Asthma | 09/25 | 12/25 | | |
|
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) |
|
|
| Recruiting | 3 | 637 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 05/25 | 05/25 | | |
FORASMA, NCT05735431: Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil |
|
|
| Not yet recruiting | 3 | 132 | RoW | Administration of investigation drug, Formoterol 6 mcg/fluticasone 125 mcg, Administration of comparator, Alenia® 6 mcg/200 mcg | Eurofarma Laboratorios S.A. | Moderate Asthma | 05/26 | 07/26 | | |
| Active, not recruiting | 3 | 323 | Canada | Vitamin D, Cholecalciferol, Placebo | Professor Francine Ducharme, Canadian Institutes of Health Research (CIHR), EURO-PHARM International Canada, Inc. | Asthma | 12/24 | 12/24 | | |
| Recruiting | 3 | 1700 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 09/25 | 09/25 | | |
|
| Active, not recruiting | 3 | 699 | Europe | STALORAL® Birch 300 IR | Stallergenes Greer, STALLERGENES | Allergic Rhinoconjunctivitis, Birch Pollen Allergy | 07/25 | 11/25 | | |
HAS3, NCT04699604: A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma |
|
|
| Recruiting | 3 | 300 | US | Levocetirizine Dihydrochloride, Xyzal, Placebo | Bridgette Jones, National Institutes of Health (NIH) | Allergic Asthma | 05/25 | 05/25 | | |
EXHALE-2, NCT05763121: A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. |
|
|
| Recruiting | 3 | 1395 | Europe, US, RoW | Dexpramipexole Dihydrochloride, Placebo | Areteia Therapeutics | Eosinophilic Asthma, Asthma; Eosinophilic, Asthma | 06/26 | 07/26 | | |
EXHALE-3, NCT05813288: A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma |
|
|
| Recruiting | 3 | 930 | Europe, US, RoW | Dexpramipexole Dihydrochloride, Placebo | Areteia Therapeutics | Eosinophilic Asthma, Asthma; Eosinophilic, Asthma | 06/26 | 07/26 | | |
NCT05776927: A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. |
|
|
| Not yet recruiting | 3 | 304 | NA | QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149, Placebo to Salmeterol Xinafoate / Fluticasone Propionate, Run-In Medication, Rescue Medication, Concept 1 Device, Girohaler | Novartis Pharmaceuticals | Asthma | 03/26 | 08/27 | | |
NCT05562466: A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma |
|
|
| Recruiting | 3 | 200 | Europe, RoW | QMF149, Budesonide | Novartis Pharmaceuticals | Asthma | 05/26 | 06/26 | | |
NCT06052267: A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations |
|
|
| Recruiting | 3 | 2196 | Europe, Canada, US, RoW | TEV-56248, Albuterol sulfate | Teva Branded Pharmaceutical Products R&D, Inc. | Asthma | 07/26 | 07/26 | | |
HORIZON, NCT06023589: A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma |
|
|
| Recruiting | 3 | 372 | Europe, Canada, Japan, US, RoW | Tezepelumab, MEDI9929 and AMG157, Placebo | AstraZeneca, Amgen | Asthma | 04/27 | 12/27 | | |
| Active, not recruiting | 3 | 760 | RoW | EpiCeram | University of Melbourne, National Health and Medical Research Council, Primus Pharmaceuticals | Eczema, Asthma, Allergy;Food | 05/27 | 05/27 | | |
DOMINICA, NCT05692180: A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma |
|
|
| Recruiting | 3 | 200 | Europe, Canada, US, RoW | Benralizumab, Placebo | AstraZeneca, Parexel | Asthma | 05/30 | 05/32 | | |
| Recruiting | 2/3 | 1125 | US | GP MDI 28.8 μg, GP, GP MDI 14.4 μg, GP MDI 7.2 μg, Placebo MDI, Placebo, Spiriva Respimat 2.5 μg, Spiriva Respimat | AstraZeneca, AstraZeneca | Asthma | 07/19 | 07/19 | | |
NCT04465175: Double Dose Magnesium Sulphate in Moderate-severe Asthma in Paediatrics |
|
|
| Not yet recruiting | 2/3 | 90 | NA | Magnesium Sulfate, MgSO4, Placebo, Normal saline | Oman Medical Speciality Board | Asthma in Children | 12/21 | 12/21 | | |
2021-006533-19: Study to assess the efficacy and safety of subcutaneous immunotherapy in patients suffering from grass pollen allergy |
|
|
| Not yet recruiting | 2/3 | 488 | Europe | CLUSTOID Phleum pratense, Suspension for injection | ROXALL Medizin GmbH, ROXALL Medizin GmbH | Patients with grass pollen-related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthma, Patients with grass pollen-related hay fever (allergic rhinitis, rhino-conjunctivitis, and well-controlled mild-to-moderate or without asthma), Diseases [C] - Immune System Diseases [C20] | | | | |
2019-002849-38: A clinical study to assess the safety, systemic exposure and efficacy of a liquid for inhalation of budesonide (AQ001S) to treat asthma. étude de la sécurité, de l’exposition systémique et de l’efficacité d’un liquide pour inhalation de budésonide dans le traitement de l’asthme |
|
|
| Not yet recruiting | 2/3 | 24 | Europe | Budesonide inhalation solution 0.125 mg/ml, Nebbud 0.25 mg/2 ml, AQ001S 0.125 mg/ml, Inhalation solution, Nebbud 0.25 mg/2 ml zawiesina do nebulizacji | Aquilon Pharmaceuticals, Walloon Region (SPW-EER) | asthma, asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT04265105: Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults |
|
|
| Completed | 2/3 | 18 | RoW | fluticasone-vilanterol, Standard Preparation, standard of care | Royal College of Surgeons in Ireland - Medical University of Bahrain | Asthma | 01/23 | 01/23 | | |
2022-001610-19: Study to assess the efficacy and safety of subcutaneous immunotherapy in patients suffering from house dust mite allergy |
|
|
| Not yet recruiting | 2/3 | 832 | Europe | CLUSTOID D. pteronyssinus, Suspension for injection, CLUSTOID D. pteronyssinus | ROXALL Medizin GmbH, ROXALL Medizin GmbH | Patients with house dust mite-related allergic rhinitis/rhino-conjunctivitis and with well-controlled mild-to-moderate or without asthma, Patients with house dust mite-related allergies and mild-to-moderate asthma (allergic rhinitis/rhino-conjunctivitis and with well-controlled mild-to-moderate or without asthma), Diseases [C] - Immune System Diseases [C20] | | | | |
2021-005169-41: Clinical study to assess the efficacy and safety of sublingual allergen immunotherapy spray in patients suffering from house dust mite allergy |
|
|
| Not yet recruiting | 2/3 | 996 | Europe | SULGEN® Spray D. pteronyssinus, Sublingual spray, solution | ROXALL Medizin GmbH, ROXALL Medizin GmbH | Patients with house dust mites related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthma, Inflammation of the nose and/or eyes and asthma caused by house dust mites, Diseases [C] - Immune System Diseases [C20] | | | | |
2022-001587-97: Study to assess the efficacy and safety of subcutaneous immunotherapy in patients suffering from birch pollen-related allergy |
|
|
| Not yet recruiting | 2/3 | 560 | Europe | CLUSTOID Birke, Suspension for injection | ROXALL Medizin GmbH, ROXALL Medizin GmbH | Patients with birch pollen-related allergic rhinitis/rhinoconjunctivitis and with well-controlled mild-to-moderate or without asthma, Patients with birch pollen-related hay fever and mild-to-moderate asthma or without asthma, Diseases [C] - Immune System Diseases [C20] | | | | |
| Recruiting | 2/3 | 100 | US | Azithromycin, Zithromax | Johns Hopkins All Children's Hospital | Pediatric Asthma, Critical Illness | 06/25 | 06/25 | | |
| Recruiting | 2/3 | 30 | US | Terbutaline | Kanecia Obie Zimmerman, Duke Health, The Emmes Company, LLC | Asthma | 12/25 | 12/25 | | |
ALOHA, NCT05251402: Addressing Quality of Life, Clinical Outcomes, and Mechanisms in Uncontrolled Asthma Following the DASH Dietary Pattern |
|
|
| Recruiting | 2/3 | 320 | US | Group A - Patient Education, Group B - Patient Education with Nutrition Counseling | University of Illinois at Chicago, Stanford University, University of Vermont, University of Newcastle, Australia, National Heart, Lung, and Blood Institute (NHLBI), University of Chicago | Asthma | 06/26 | 09/26 | | |
MM09-SLIM, NCT05641272: Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract |
|
|
| Not yet recruiting | 2/3 | 90 | RoW | 3,000 MM09, 9,000 MM09, Placebo sublingual | Inmunotek S.L., LAT Research, Xolomon Tree S.L. | Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite | 06/26 | 12/26 | | |
NCT05761028: A Study of CM310 in Subjects With Moderate to Severe Asthma |
|
|
| Recruiting | 2/3 | 600 | RoW | CM310, Placebo | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Moderate to Severe Asthma | 05/32 | 05/32 | | |
